Search

Now showing items 1-9 of 9

Positive impact of cladribine on quality of life in people with relapsing multiple sclerosis

Afolabi, D; Albor, C; Zalewski, L; Altmann, DR; Baker, D; Schmierer, K (2018-10)

Disease activity in progressive multiple sclerosis can be effectively reduced by cladribine

Yildiz, O; Mao, Z; Adams, A; Dubuisson, N; Allen-Philbey, K; Giovannoni, G; Malaspina, A; Baker, D; Gnanapavan, S; Schmierer, K (2018-08)

Cladribine: Off-label disease modification for people with multiple sclerosis in resource-poor settings?

Mao, Z; Álvarez-Gonzalez, C; De Trane, S; Yildiz, O; Albor, C; Doctor, G; Soon, D; Pepper, G; Turner, BP; Marta, M;... (2018-04)

Background: A considerable number of people with multiple sclerosis (pwMS) live in low- and middle-income countries (LMIC), where lack of resource adversely affects access to effective disease-modifying treatment. Objective: ...

Cladribine treatment of multiple sclerosis is associated with depletion of memory B cells

Ceronie, B; Jacobs, BM; Baker, D; Dubuisson, N; Mao, Z; Ammoscato, F; Lock, H; Longhurst, HJ; Giovannoni, G; Schmierer, K (2018-05)

Treating the ineligible: Disease modification in people with multiple sclerosis beyond NHS England commissioning policies.

Mao, Z; Álvarez-González, C; Allen-Philbey, K; De Trane, S; Yildiz, O; Campion, T; Adams, A; Turner, BP; Marta, M; Gnanapavan, S;... (Elsevier/Science Direct, 2018-11-02)

BACKGROUND: Whilst there is a broad selection of drugs licensed as disease modifying treatments (DMTs) for people with relapsing multiple sclerosis (pwRMS), access to DMTs remains restricted, particularly for people with ...

Severe skin reactions associated with cladribine in people with multiple sclerosis

Mateo-Casas, M; Reyes, S; O'Toole, EA; De Trane, S; Yildiz, O; Allen-Philbey, K; Mathews, J; Baker, D; Giovannoni, G; Schmierer, K (2020-08)

Severe lymphopenia after subcutaneous cladribine in a patient with multiple sclerosis: To vaccinate or not?

Mateo-Casas, M; Reyes, S; De Trane, S; Edwards, F; Espasandin, M; Anjorin, G; Baker, D; Schmierer, K; Giovannoni, G (2020-10-09)

Objective: To describe a fatal case of influenza A pneumonia in a patient with severe lymphopenia after receiving subcutaneous cladribine to treat her multiple sclerosis (MS). Methods: Case report. Results: A 53-year-old ...

CD19 B cell repopulation after ocrelizumab, alemtuzumab and cladribine: Implications for SARS-CoV-2 vaccinations in multiple sclerosis

Baker, D; MacDougall, A; Kang, AS; Schmierer, K; Giovannoni, G; Dobson, R (2022)

Cladribine tablets in relapsing-remitting multiple sclerosis preferentially target B-cells.

Ammoscato, F; Wafa, M; Skonieczna, J; Bestwick, J; Monero, R; Andrews, M; De Trane, S; Holden, D; Adams, A; Bianchi, L;... (Elsevier, 2024-10-18)

Recent studies demonstrate the efficacy of B cell-targeting therapies in managing multiple sclerosis (MS) activity, emphasizing the critical role of B cells in MS pathogenesis. CladB study aimed to quantify the temporal ...